(5E,8E,10E,12S,14E)-12-hydroxyicosa-5,8,10,14-tetraenoic acid | 55821-52-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (5E,8E,10E,12S,14E)-12-hydroxyicosa-5,8,10,14-tetraenoic acid
• CAS: 55821-52-8
• 化学式: C₂₀H₃₂O₃
• 分子量: 320.5
• InChiKey: ZNHVWPKMFKADKW-XMWPZNECSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  23
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• POLY(PHOSPHOESTERS) FOR DELIVERY OF NUCLEIC ACIDS
  申请人：TRANSLATE BIO, INC.

  公开号：US20200277446A1

  公开（公告）日：2020-09-03

  Disclosed are polymers comprising the moiety A, which is a moiety of formula I: and pharmaceutically acceptable salts thereof, wherein R, R 1 , R 2 , L, n1 and n2 are as defined herein. These polymers are useful for delivering nucleic acids to subject. These polymers and pharmaceutically acceptable compositions comprising such polymers and nucleic acids can be useful for treating various diseases, disorders and conditions.

  揭示了包含A基团的聚合物，该基团是化学式I的基团：及其药用可接受的盐，其中R、R1、R2、L、n1和n2如本文所定义。这些聚合物对于将核酸传递给受试者是有用的。这些聚合物和包含这些聚合物和核酸的药用可接受组合物可用于治疗各种疾病、疾病和症状。
• LIPIDIC NANOPARTICLES FOR MRNA DELIVERY IN THE LUNGS
  申请人：Translate Bio, Inc.

  公开号：EP3628335A1

  公开（公告）日：2020-04-01

  Disclosed herein are compositions for use in am method of treating a disease in a subject, wherein the disease is due to a deficiency of a pulmonary surfactant-associated protein. The composition comprises mRNAs encoding the pulmonary surfactant-associated protein and a lipid nanoparticle that comprises cationic lipids, anionic lipids and PEG-modified lipids. The composition is to be administered via the pulmonary route.

  本文公开了用于治疗受试者疾病的方法的组合物，其中疾病是由于肺表面活性物质相关蛋白的缺乏引起的。组合物包括编码肺表面活性物质相关蛋白的 mRNA 和脂质纳米颗粒，脂质纳米颗粒包括阳离子脂质、阴离子脂质和 PEG 改性脂质。该组合物通过肺部途径给药。
• Lipid formulations for delivery of messenger RNA
  申请人：Translate Bio, Inc.

  公开号：US10052284B2

  公开（公告）日：2018-08-21

  The present invention provides, among other things, methods of delivering mRNA in vivo, including administering to a subject in need of delivery a composition comprising an mRNA encoding a protein, encapsulated within a liposome such that the administering of the composition results in the expression of the protein encoded by the mRNA in vivo, wherein the liposome comprises a cationic lipid of formula I-c: or a pharmaceutically acceptable salt thereof.

  本发明除其他外提供了体内递送 mRNA 的方法，包括向需要递送的受试者施用包含编码蛋白质的 mRNA 的组合物，该组合物封装在脂质体中，施用该组合物后，mRNA 所编码的蛋白质在体内表达，其中脂质体包含式 I-c 的阳离子脂质： 或其药学上可接受的盐。
• Pulmonary delivery of mRNA to non-lung target cells
  申请人：Shire Human Genetic Therapies, Inc.

  公开号：US10245229B2

  公开（公告）日：2019-04-02

  Compositions comprising mRNA formulated for pulmonary administration and related methods for delivery of the mRNA and/or encoded protein to a non-lung cell or tissue. The compositions and methods may be used to prevent or ameliorate the symptoms of diseases associated with the mRNA encoded protein.

  包含配制成肺部用药的 mRNA 的组合物，以及将 mRNA 和/或编码蛋白输送到非肺部细胞或组织的相关方法。这些组合物和方法可用于预防或改善与 mRNA 编码蛋白相关的疾病症状。
• Multimeric coding nucleic acid and uses thereof
  申请人：Translate Bio, Inc.

  公开号：US10266843B2

  公开（公告）日：2019-04-23

  The present invention provides, among other things, multimeric coding nucleic acids that exhibit superior stability for in vivo and in vitro use. In some embodiments, a multimeric coding nucleic acid (MCNA) comprises two or more encoding polynucleotides linked via 3′ ends such that the multimeric coding nucleic acid compound comprises two or more 5′ ends.

  本发明提供的多聚体编码核酸在体内和体外使用时具有优异的稳定性。在某些实施方案中，多聚编码核酸（MCNA）包括两个或两个以上通过 3′末端连接的编码多核苷酸，从而使多聚编码核酸化合物包括两个或两个以上 5′末端。